Federal drug-pricing plan threatens access to new medicines
There’s no escaping the fact that discovering, developing and testing new drugs costs a lot of money
Read More
Author: Steven Globerman
Despite government subsidies, Canadian innovation wanes
Burdensome regulation, limited competition and unfavourable taxes hold Canadian companies back
Read More
Canada’s free ride on U.S. drug development may end soon
A shift in U.S. drug pricing could cut pharmaceutical profits, meaning less money for research and development
Read More
Wake up Canada, you have a business investment crisis
There’s been no growth in years in the corporate assets that help make companies more efficient and profitable
Read More
The Canadian economy is at the precipice
From uncertain trade talks to lack of affordable housing to rising interest rates to government debt, the warning signs are rising
Read More